Poland combines one of Europe's largest pools of life-science graduates with full integration into the European Union's regulatory framework — including EMA procedures, EU GMP standards and the single market.
Development economics matter for emerging pharmaceutical companies. Central-European operating costs allow capital to be directed toward evidence generation rather than overhead, without compromising regulatory credibility.
The region's clinical infrastructure — academic centres, experienced investigators and high trial-enrolment performance — has made it an established destination for international clinical development.
ObNowa Pharma's decision to headquarter in Poland reflects this calculus: European regulatory alignment, scientific depth and capital efficiency in a single base.
This article reflects ObNowa Pharma's corporate perspective and is provided for general information.
Development status — all programs presented are currently in research and development. Potential indications and applications reflect development objectives and do not represent established efficacy, safety or regulatory approval.